PhoenixBio Co (TSE:6190) Cyclically Adjusted Revenue per Share: 円464.59 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:6190 PhoenixBio Co Ltd TSE:6190
51 GF Score
Price 円351.00
GF Value 円364.30
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is PhoenixBio Co Cyclically Adjusted Revenue per Share?

PhoenixBio Co TSE:6190 -0.28% 51 Cyclically Adjusted Revenue per Share is 円464.59 as of Mar. 2026. GuruFocus rates TSE:6190 with a GF Score™ of 51/100 and a GF Value™ of 円364.30 (Fairly Valued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

PhoenixBio Co's adjusted revenue per share for the three months ended in Mar. 2026 was 円89.636. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円464.59 for the trailing ten years ended in Mar. 2026.

During the past 12 months, PhoenixBio Co's average Cyclically Adjusted Revenue Growth Rate was -1.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-15), PhoenixBio Co's current stock price is 円351.00. PhoenixBio Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was 円464.59. PhoenixBio Co's Cyclically Adjusted PS Ratio of today is 0.76.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of PhoenixBio Co was 1.12. The lowest was 0.67. And the median was 0.87.


PhoenixBio Co  (TSE:6190) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

PhoenixBio Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=351.00/464.59
=0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of PhoenixBio Co was 1.12. The lowest was 0.67. And the median was 0.87.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


PhoenixBio Co Cyclically Adjusted Revenue per Share Related Terms


PhoenixBio Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for PhoenixBio Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PhoenixBio Co Cyclically Adjusted Revenue per Share Chart

PhoenixBio Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 464.59

PhoenixBio Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 468.63 464.59

TSE:6190 vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, PhoenixBio Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PhoenixBio Co Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PhoenixBio Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where PhoenixBio Co's Cyclically Adjusted PS Ratio falls into.


TSE:6190
51GF Score
PhoenixBio Co Ltd TSE:6190
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PhoenixBio Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PhoenixBio Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=89.636/112.7000*112.7000
=89.636

Current CPI (Mar. 2026) = 112.7000.

PhoenixBio Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 144.395 97.900 166.224
201606 114.253 98.100 131.257
201609 76.203 98.000 87.633
201612 118.389 98.400 135.594
201703 113.994 98.100 130.959
201706 42.745 98.500 48.907
201709 66.359 98.800 75.695
201712 113.133 99.400 128.271
201803 88.546 99.200 100.596
201806 54.678 99.200 62.119
201809 91.652 99.900 103.395
201812 138.238 99.700 156.263
201903 135.991 99.700 153.723
201906 98.813 99.800 111.585
201909 79.424 100.100 89.421
201912 106.060 100.500 118.935
202003 162.856 100.300 182.990
202006 52.872 99.900 59.646
202009 42.358 99.900 47.785
202012 60.659 99.300 68.845
202103 155.821 99.900 175.786
202106 137.484 99.500 155.723
202109 56.203 100.100 63.278
202112 89.250 100.100 100.484
202203 118.436 101.100 132.025
202206 134.599 101.800 149.011
202209 207.412 103.100 226.725
202212 154.127 104.100 166.860
202303 127.617 104.400 137.763
202306 120.815 105.200 129.428
202309 117.899 106.200 125.115
202312 110.942 106.800 117.071
202403 96.000 107.200 100.925
202406 111.507 108.200 116.145
202409 83.945 108.900 86.874
202503 0.000 111.100 0.000
202506 98.828 111.700 99.713
202509 87.731 112.000 88.279
202512 109.367 113.000 109.077
202603 89.636 112.700 89.636

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円464.59 mean?
PhoenixBio Co (TSE:6190) has a Cyclically Adjusted Revenue per Share of 円464.59 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on PhoenixBio Co and its competitors.
Is PhoenixBio Co's Cyclically Adjusted Revenue per Share too high?
PhoenixBio Co's current Cyclically Adjusted Revenue per Share is 円464.59. Overall, PhoenixBio Co has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PhoenixBio Co's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
PhoenixBio Co's Cyclically Adjusted Revenue per Share of 円464.59 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on PhoenixBio Co and its competitors. PhoenixBio Co's current Cyclically Adjusted Revenue per Share is 円464.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhoenixBio Co stock overvalued right now?
Based on GuruFocus' analysis, PhoenixBio Co (TSE:6190) is currently considered Fairly Valued. The stock's GF Value™ is 円364.30, compared to a current price of 円351.00 — trading 3.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円464.59. PhoenixBio Co's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For PhoenixBio Co (TSE:6190), the current Cyclically Adjusted Revenue per Share is 円464.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PhoenixBio Co (TSE:6190) Overvalued in 2026?

Based on GuruFocus' analysis, PhoenixBio Co stock appears to be undervalued. The current stock price of 円351.00 is trading 3.7% below its estimated GF Value™ of 円364.30. GuruFocus considers PhoenixBio Co to be Fairly Valued.

Key valuation signals for TSE:6190:

  • Cyclically Adjusted Revenue per Share: 円464.59
  • GF Value™: 円364.30 vs. price of 円351.00 (3.7% below fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the TSE:6190 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PhoenixBio Co Business Description

Address 3-4-1, Kagamiyama, Hiroshima Prefecture, Higashi-Hiroshima, JPN, 739-0046
PhoenixBio Co Ltd conducts study services for drug discovery and early development. It provides outsourcing services for drug development. The Company uses PXB-Mouse to conduct the study. Its services include pharmacokinetics-related tests, safety tests, and hepatitis virus (HBV / HCV) related drug efficacy tests. Geographically, the company generates the majority of its revenue from USA.
51GF Score

Get the complete analysis for TSE:6190

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円351.00
Price
円364.30
GF Value